In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Dr Collins discusses the significant shifts in treatment approaches for patients with advanced-stage classical Hodgkin lymphoma over the past decade. He also explores the excitement around newer regimens, including nivolumab-AVD, BV-AVD, and more. To conclude, Dr Collins shares his approach to treating patients with relapsed disease, drawing focus on the role of autologous stem cell transplantation.

Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently in Miami, FL. First you will hear from Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Mohammad Rashidian, PhD, Dana-Farber Cancer Institute, Boston, MA, Michael Jain, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, who explore outcomes of treatment with CAR T-cells and potential strategies to enhance their efficacy and minimize toxicities.

Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, then provides insight into his keynote talk on accelerating CAR T-cell therapeutics with small molecules and CRISPR 2.0 gene editing. This is followed by Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tara Graff, DO, MS, Mission Cancer and Blood, Des Moines, IA, and Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA, who share their perspectives on how to improve access and delivery of T-cell engaging therapies in the community.

This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, who provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations. They explore treatment strategies at first relapse and for double-refractory patients, including fixed-duration combinations and the emerging role of the non-covalent BTK inhibitor, pirtobrutinib. Additionally, the experts share their perspectives on the role of allogeneic stem cell transplantation and CAR T-cell therapy, and offer a glimpse into promising therapies on the horizon, such as BTK degraders and bispecific antibodies.

VJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL. This podcast episode features highlights from the meeting.

First, you will hear from Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Thomas Martin, MD, University of California San Francisco, San Francisco, CA, and Adriana Rossi, MD, Mount Sinai, New York City, NY, who share updates with the use of several agents in multiple myeloma. Damian Green, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, and Rachid Baz, MD, Moffitt Cancer Center, Tampa, FL, will then discuss practical considerations when using T-cell therapies, including managing adverse events and improving access.

In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). They cover key topics such as diagnostic advancements, frontline treatment strategies based on IGHV mutational status, the role of double oral combinations, the importance of measurable residual disease (MRD)-guided treatment, and the debate between time-limited and continuous regimens.

In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation.

Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, provide insights into current treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll hear about cytomegalovirus (CMV) management from Per Ljungman, MD, PhD, Karolinska Institute, Stockholm, Sweden, and human herpesvirus 6 (HHV-6) diagnosis from Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, and Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy.

Finally, Manuela Spadea, MD, University of Turin, Turin, Italy, comments on ushering in the era of the hematologist-AI alliance, and Adrián Mosquera-Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, highlights the potential for harnessing machine learning to predict post-SCT outcomes in patients with myelofibrosis (MF).

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). They focus on the sequencing of CAR T-cells and bispecific antibodies in diffuse large B-cell lymphoma (DLBCL), the use of BTK inhibitors (BTKis) in mantle cell lymphoma (MCL), and advances in the treatment of follicular lymphoma.